Adjunctive Nutritional Supplementation in Drug-Resistant Epilepsy: A Prospective Observational Study Evaluating Quality of Life and Seizure Outcomes

辅助营养补充治疗耐药性癫痫:一项评估生活质量和癫痫发作结果的前瞻性观察研究

阅读:1

Abstract

INTRODUCTION: Drug-resistant or refractory epilepsy remains a significant clinical challenge, with persistent seizures and impaired quality of life, despite optimized antiepileptic therapy. Increasing attention has been directed toward adjunctive nutritional strategies that may support neuronal stability and overall well-being. The aim of the present study was to evaluate the real-world impact of Epregres Unique 12 as an adjunct to standard antiepileptic drug therapy on the quality of life and seizure frequency in patients with drug-resistant epilepsy. MATERIALS AND METHODS: This prospective observational study was conducted at a tertiary care center between January 2023 and December 2024. Twenty-six patients with drug-resistant epilepsy were followed for 12 weeks after the initiation of adjunctive nutritional supplementation. Antiepileptic drug regimens were continued without protocol-driven modifications. The quality of life was assessed using the Quality of Life in Epilepsy-31 (QOLIE-31) questionnaire at baseline and after 12 weeks. Seizure frequency was documented by using patient-maintained seizure diaries. Data were analyzed using paired statistical tests with effect size estimation. RESULTS: Twenty-six patients (19 males, seven females; mean age 37.2 ± 7.4 years) were included. Emotional well-being showed a statistically significant improvement at 12 weeks (p = 0.009) with a moderate effect size. The total QOLIE-31 score demonstrated a clinically meaningful improvement, approaching statistical significance (p = 0.061). Seizure frequency decreased in 20 (76.9%) patients, including complete seizure cessation in 6 (23.1%) patients. The supplement was well-tolerated, with only one minor adverse event reported. CONCLUSION: Adjunctive nutritional supplementation is associated with improvements in emotional well-being and favorable trends in quality of life and seizure frequency in patients with drug-resistant epilepsy. While these findings are encouraging, controlled studies with larger sample sizes are required to confirm these observations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。